Aggregate-data estimation of an individual patient data linear random effects meta-analysis with a patient covariate-treatment interaction term

Individual patient-data meta-analysis of randomized controlled trials is the gold standard for investigating how patient factors modify the effectiveness of treatment. Because participant data from primary studies might not be available, reliable alternatives using published data are needed. In this...

Full description

Saved in:
Bibliographic Details
Published inBiostatistics (Oxford, England) Vol. 14; no. 2; pp. 273 - 283
Main Author Kovalchik, Stephanie A.
Format Journal Article
LanguageEnglish
Published England Oxford Publishing Limited (England) 01.04.2013
Oxford University Press
Subjects
Online AccessGet full text
ISSN1465-4644
1468-4357
1468-4357
DOI10.1093/biostatistics/kxs035

Cover

More Information
Summary:Individual patient-data meta-analysis of randomized controlled trials is the gold standard for investigating how patient factors modify the effectiveness of treatment. Because participant data from primary studies might not be available, reliable alternatives using published data are needed. In this paper, I show that the maximum likelihood estimates of a participant-level linear random effects meta-analysis with a patient covariate-treatment interaction can be determined exactly from aggregate data when the model's variance components are known. I provide an equivalent aggregate-data EM algorithm and supporting software with the R package ipdmeta for the estimation of the "interaction meta-analysis" when the variance components are unknown. The properties of the methodology are assessed with simulation studies. The usefulness of the methods is illustrated with analyses of the effect modification of cholesterol and age on pravastatin in the multicenter placebo-controlled regression growth evaluation statin study. When a participant-level meta-analysis cannot be performed, aggregate-data interaction meta-analysis is a useful alternative for exploring individual-level sources of treatment effect heterogeneity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1465-4644
1468-4357
1468-4357
DOI:10.1093/biostatistics/kxs035